denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm & Oncopeptides. Provided by the Annenberg Center for Health Sciences at Eisenhower. In partnership with Clinical Care Options, LLC & the International Myeloma Foundation.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
ALL, Follicular Lymphoma, multiple myeloma, antibodies, therapy sequence, Biological, Adult, CLL, Marginal Zone Lymphoma, smoldering myeloma, Diseases, LGLL, Mantle Cell Lymphoma, CAR-Ts, Therapies, Combinations, Elderly, CNS Lymphoma, DLBCL, Biological Processes, Technology and Procedures, immunotherapy, Study Population, NK cells, Myeloid Malignancies, molecular testing, microenvironment
Hematology Disease Topics & Pathways:
ALL, Follicular Lymphoma, multiple myeloma, antibodies, therapy sequence, Biological, Adult, CLL, Marginal Zone Lymphoma, smoldering myeloma, Diseases, LGLL, Mantle Cell Lymphoma, CAR-Ts, Therapies, Combinations, Elderly, CNS Lymphoma, DLBCL, Biological Processes, Technology and Procedures, immunotherapy, Study Population, NK cells, Myeloid Malignancies, molecular testing, microenvironment
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Brian G.M. Durie, MD, Cedars Sinai Cancer Center
Disclosures:
Durie: Amgen, Celgene, Johnson & Johnson, and Takeda: Consultancy.
Speakers:
S. Vincent Rajkumar, MD, Mayo Clinic
,
Shaji K. Kumar, MD, Mayo Clinic Rochester, Division of Hematology
,
Philippe Moreau, MD, Nantes University Hospital
,
Jesús F. San-Miguel, University of Navarra
and
Thomas Martin, MD, University of California
Disclosures:
Kumar: Cellectar: Other; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Sanofi: Research Funding; MedImmune: Research Funding; Merck: Consultancy, Research Funding; Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Adaptive Biotechnologies: Consultancy; Genecentrix: Consultancy; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Dr. Reddy's Laboratories: Honoraria; Carsgen: Other, Research Funding; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; Kite Pharma: Consultancy, Research Funding; AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Novartis: Research Funding; Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Karyopharm: Consultancy; BMS: Consultancy, Research Funding; Tenebio: Other, Research Funding. Moreau: Takeda: Consultancy; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Sanofi: Honoraria. San-Miguel: Bristol-Myers Squibb, Celgene, Novartis, Takeda, Amgen, MSD, Janssen, and Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche, AbbVie, GlaxoSmithKline, and Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees. Martin: Sanofi, Amgen, Seattle Genetics, JNJ - Janssen: Research Funding; Legend Biotech: Consultancy.
Attendees of this annual International Myeloma Foundation/Clinical Care Options cosponsored program can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. This international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice. As part of panel discussion, the experts will debate clinical questions, review available evidence and challenges that affect therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and submit questions directly to the panel for their consideration. Discussion topics include:
Case Discussion 1: Early Treatment for High-Risk Smoldering MM
Case Discussion 2: Individualized Approaches to Frontline Treatment Selection
Case Discussion 3: Managing the Patient With Relapsed Disease After ≥ 1 Lines of Therapy
Case Discussion 4: Understanding the Different Anti-BCMA Therapies
Panel Discussion: Future Directions and a New 2021 Treatment Algorithm for MM
See more of: Satellite Symposia